Mark Daniel Hicar, MD, PhD, FPIDS, FIDSA; Associate Professor, University at Buffalo; Interim Chief, Pediatric Infectious Diseases (PID) Division; Fellowship Director, PID Division. Dr. Hicar trained at the University of Chicago, obtained an MD and a PhD The Ohio State University, and then did residency and fellowship training at Vanderbilt University. The Hicar lab currently focuses on B-cell responses during inflammation to develop novel vaccine targets. Our lab has done extensive work in HIV and Kawasaki disease with novel paths into Multisystem Inflammatory Syndrome in children (MIS-C) and Alzheimer's disease. With HIV, the Hicar lab has used human-derived monoclonal antibodies to identify novel epitopes on the HIV envelope. The Hicar lab is targeting these as novel immunogens in vaccine development. The vasculitis Kawasaki Disease is the leading cause of acquired heart disease in children and primarily affects children under 5 years of age. The Hicar lab is using antibody responses to attempt to discover the cause. Similar approaches are being used to explore the infectious disease relationship to Alzheimer's development. Select awards: 2009 Infectious Diseases Society of America (IDSA), ERF/NFID Wyeth Young Investigator Award in Vaccine Development; elected to Society for Pediatric Research; Fellow, Pediatric Infectious Diseases Society; Fellow, Infectious Diseases Society of America.
Short Biography
Mark Daniel Hicar, MD, PhD, FPIDS, FIDSA; Associate Professor, University at Buffalo; Interim Chief, Pediatric Infectious Diseases (PID) Division; Fellowship Director, PID Division. Dr. Hicar trained at the University of Chicago, obtained an MD and a PhD The Ohio State University, and then did residency and fellowship training at Vanderbilt University. The Hicar lab currently focuses on B-cell responses during inflammation to develop novel vaccine targets. Our lab has done extensive work in HIV and Kawasaki disease with novel paths into Multisystem Inflammatory Syndrome in children (MIS-C) and Alzheimer's disease. With HIV, the Hicar lab has used human-derived monoclonal antibodies to identify novel epitopes on the HIV envelope. The Hicar lab is targeting these as novel immunogens in vaccine development. The vasculitis Kawasaki Disease is the leading cause of acquired heart disease in children and primarily affects children under 5 years of age. The Hicar lab is using antibody responses to attempt to discover the cause. Similar approaches are being used to explore the infectious disease relationship to Alzheimer's development. Select awards: 2009 Infectious Diseases Society of America (IDSA), ERF/NFID Wyeth Young Investigator Award in Vaccine Development; elected to Society for Pediatric Research; Fellow, Pediatric Infectious Diseases Society; Fellow, Infectious Diseases Society of America.
Advance your academic career, collaborate globally, and expand your network—
join now
!
Well done!
